Table 2. Active studies with immune checkpoint inhibitors for stage III, unresectable NSCLC.
| Drug | Phase | Enrollment | Sponsor | Primary endpoint(s) | Timing of immunotherapy | ClinicalTrials.gov identifier |
|---|---|---|---|---|---|---|
| PD-L1 inhibitors | ||||||
| Durvalumab | III | 300 | AstraZeneca | PFS, OS | Concurrent, consolidative | NCT03519971 |
| Atezolizumab | II | 52 | M.D. Anderson | Grade 3–4 non-hematologic toxicities | Consolidation | NCT02525757 |
| Atezolizumab | II | 63 | Alliance Foundation Trials, LLC | Disease control rate | Induction, consolidative | NCT03102242 |
| PD-1 inhibitors | ||||||
| Nivolumab | II | 78 | European Thoracic Oncology Platform | Grade 3+ pneumonitis | Concurrent, consolidative | NCT02434081 |
| Nivolumab (with Ipilimumab) | II | 108 | Big Ten Cancer Research Consortium | PFS | Consolidative | NCT03285321 |
| Pembrolizumab | II | 93 | Hoosier Cancer Research Network | Time to death or distant metastasis | Consolidative | NCT02343952 |
| Pembrolizumab | I | 30 | Rutgers | MTD, DLT | Various: 2–6 weeks post-CRT OR 2 weeks before end of CRT OR start of CRT | NCT02621398 |
NSCLC, non-small cell lung cancer; PD-L1, programmed death-ligand 1; PFS, progression-free survival; OS, overall survival; PD-1, programmed cell death protein 1; MTD, maximum tolerated dose; DLT, dose limiting toxicity; CRT, chemo/radiotherapy.